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Abstract  
Significant progress has been made in the development, validation and regulatory 
acceptance of in chemico and in vitro test methods for skin sensitisation. Although these 
methods have been shown to perform relatively well (about 80% accuracy in predicting 
Local Lymph Node Assay (LLNA) classifications) a concern was raised on the regulatory 
acceptability of negative results since it was questioned whether these methods are able 
to predict chemicals that need to be activated to act as sensitisers.  
In order to inform ongoing discussions at the regulatory level in the EU, EURL ECVAM 
held an expert meeting on 10-11 November 2015 to analyse the extent to which in 
chemical and in vitro methods are able to correctly identify chemicals that need to be 
activated either through abiotic activation (pre-haptens) and/or through biotic (enzyme-
mediated) mechanisms (pro-haptens) to acquire skin sensitisation potential.  
The expert group analysed a list of 127 chemicals, with available LLNA and in vitro data, 
22% of which were considered to be pre- and/or pro-haptens. The pre-haptens, 
constituting the vast majority of chemicals requiring activation, were mostly correctly 
identified by both the in chemico and in vitro assays whereas the pro-haptens which 
represent a small subset of sensitising chemicals, were identified correctly by at least 
one of the cell-based assays.  
As a result, the expert group recommended that negative in vitro data should be 
accepted unless there is a compelling scientific argument that a substance is likely to be 
an exclusively metabolically activated pro-hapten. 
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1. Introduction  
In the last few decades it has become more obvious that a substantial minority of 
substances causing contact allergy are not sensitisers themselves, but need to be 
activated to become sensitising. We name them pre-haptens and pro-haptens (1). 
Pre-haptens are activated abiotically outside the skin mainly by autoxidation while pro-
haptens are activated in the skin.  Pro-haptens are most often judged to be activated 
biotically by metabolic mechanisms, although abiotic activation (e.g. oxidation) can also 
take place in the skin.  In addition, many pre-haptens can act as pro-haptens and this 
potential should be considered as and when a pre-hapten has been identified.  The same 
haptens can be formed from both activation pathways even though the mechanisms may 
be different. Activation of pre-haptens most often occurs via a radical pathway with the 
formation of highly sensitising hydroperoxides as the primary oxidation products.  Some 
of these hydroperoxides are unstable; often they cannot be detected and are only 
identified as a result of secondary oxidation products being formed (2; 3).  The 
secondary oxidation products can also be sensitisers and have for some substances (e.g. 
geraniol (4; 5) and alpha-terpinene (6; 7) been shown to be identical with those formed 
via the metabolic pathway.  However, it is important to remember that not all oxidation 
processes lead to sensitisation. 
Although the picture of activation via abiotic and biotic ways may appear quite complex, 
in silico tools such as TIMES-SS (http://oasis-lmc.org/products/models/human-health-
endpoints/skin-sensitization.aspx) (8; 9; 10) or the OECD Toolbox (http://www.oecd.org 
/chemicalsafety/risk-assessment/theoecdqsartoolbox.htm) (11), which are underpinned 
by adequate experimental data and valid (Q)SARs, may be helpful in detecting and 
discriminating between alternative activation routes. With regard to the in vitro 
methods, the complexity of the problem must be first considered so that the skin 
sensitisation potential of a new substance will be correctly identified.  
Besides the in silico approaches ((Q)SARs, expert systems and read-across, (12) 
currently available for skin sensitisation, significant developments have been made in 
the development and validation of in chemico and in vitro test methods (13; 14; 15). 
Two of these methods, the direct peptide reactivity assay (DPRA) and the 
KeratinoSensTM, have been adopted by the OECD in 2015 as TG 442C (16) and TG442D 
(17) respectively.  A third in vitro method, namely the human Cell Line Activation Test 
(h-CLAT), is in the final stages of the OECD adoption process at the time of writing of 
this report.  
Although these methods have been shown to perform relatively well in predicting LLNA 
results (accuracy about 80%) they are proposed to be used in combination with other 
information for assessing the skin sensitisation potential of chemicals. One explanation 
put forward for this is that the validated methods are only addressing parts of the 
complex biological mechanisms that lead to the acquisition of skin sensitisation. One of 
the concerns commonly raised on the suitability of the results generated with these non-
animal test methods is related to their ability to predict chemicals that need to be 
activated to act as sensitisers. The DPRA for example does not have a metabolic system 
and the two in vitro methods make use of cells that are not fully representing the in vivo 
metabolic situation. 
In order to inform ongoing discussion at the regulatory level in the EU and specifically 
the revision of the ECHA guidance on Information Requirements and Chemical Safety 
Assessment (Chapter R.7a: endpoint specific guidance) (12), the expert group 
considered the general topic of skin sensitisers which are known not to be directly acting 
substances, i.e. that require some type of “activation” before they can initiate key event 
1 (KE1) in the skin sensitisation Adverse Outcome Pathway (AOP) (18; 19).  The first 
key event in the published AOP for skin sensitisation is considered also to be the 
Molecular Initiating Event (MIE) and represents the covalent interaction with skin 
proteins.  
 5 
 
Pre-haptens require abiotic activation (e.g. air oxidation, hydrolysis) to trigger KE1; pro-
haptens require metabolic activation to trigger KE1, but abiotic activation (oxidation) 
also can take place in the skin.  The group noted that for a proportion of non-direct 
acting haptens it remains uncertain whether they are pre- or pro- (or possibly pre- and 
pro-) haptens.  It does appear that many of the substances previously suspected to be 
pro-haptens requiring metabolic activation are actually also pre-haptens (e.g. p-
phenylenediamine (20; 21), geraniol (4), cinnamic alcohol (22; 23; 24)). Consequently, 
the possibility that a substance can act both as a pre-hapten and as pro-hapten should 
be considered.   
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2. Analysis of in vivo and in vitro data  
An assessment of a published database of 319 LLNA results demonstrates that 
approximately 25% of sensitising chemicals were reported to be pre- or pro-haptens 
(25).  A similar conclusion was reached by the expert group following review of an EURL 
ECVAM dataset of 127 substances for which LLNA and non-animal data, generated with 
DPRA, h-CLAT and KeratinosensTM, was available (see table 1). Of the substances 
identified as sensitisers by the LLNA, 22% were considered to be pre- and/or pro-
haptens.  Unlike the published dataset from Kern et al. (25), a view was taken for this 
dataset on the distribution of pre- and pro-haptens (see Figure1). 
 
Figure 1: Distribution of pre-haptens and/or pro-haptens among skin sensitisers 
 
 
 
The majority of the group of non-direct acting haptens are pre-haptens, substances 
which generally were identified by the DPRA and the cell-based assays.  However, the 
rate of oxidation varies and slow oxidisers may not be identified by these methods, just 
as they might fail to be detected by the in vivo assays depending on their purity at the 
time point for the experiment.  It is therefore important that the possibility for a 
substance to be activated by oxidation is considered based on structure–activity 
relationship (SAR) analysis and if necessary autoxidation studies should be performed 
together with experimental sensitisation studies.  
The expert group agreed that the number of substances that were exclusively pro-
haptens in the EURL ECVAM dataset represented a small subset of the overall category 
of classifiable skin sensitisers. This was also consistent with the assessment by Urbisch 
and colleagues (26).  
The data analysis suggested that this pro-hapten subset (n=5) of which only one was 
identified by the DPRA, were all identified correctly by h-CLAT and two were correctly 
identified by Keratinosens™ (see Table 2).  Thus, when using in vitro methods, an 
approach might be first to conduct an assessment of KE1 (e.g. DPRA) and if this proved 
negative, then in the absence of other data to support an argument that it is non-
sensitising, there should be a follow up with a cell-based assay.  If both tests were 
negative, the substance would not be regarded as sensitising.   
The expert group agreed that all decisions relating to classification should be based on 
an assessment of the overall weight of evidence. 
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2.1 Table 1: List of chemicals with LLNA and non-animal data  
# Chemical name SMILES LLNA Human1 DPRA 
Keratino
-Sens™ 
h-CLAT 
Reaction 
Mechanistic 
Domain2 
1 
1,2,4-Benzenetricarboxylic 
anhydride (Trimellitic 
anhydride) 
O=C(OC(=O)c1ccc(C(=O)O)c2)c12 1 
 
1 0 1 Acylb 
2 
1,2-Benzisothiazolin-3-
one (Proxel active) 
O=C(NSc1cccc2)c12 1 1 1 1 1 Special case SN2b 
3 
1,2-Dibromo-2,4-
dicyanobutane (MDGN) 
C(#N)C(Br)(CCC(#N))CBr 1 1 1 1 1 pre-MA, SN2b 
4 1,4-Phenylenediamine Nc(ccc(N)c1)c1 1 1 1 1 1 pre-MAa,b 
5 1-Bromobutane BrCCCC 0 
 
1 0 1 SN2a 
6 1-Bromohexane CCCCCCBr 1 
 
1 1 0 SN2b 
7 1-Butanol OCCCC 0 0 0 0 0 non-reactive 
                                           
1 indicates a positive outcome, 0 indicates a negative outcome. 
 
1 Human data derived from Basketter et al. (27). 
 
2 Reaction mechanistic domains as defined by Aptula et al. (20): MA, Michael Acceptors; SN2, SN2 electrophiles; Acyl, acyl transfer agents; SNAr, SNAr 
electrophiles; SB, Schiff base formers. Substances that do not fall into one of these domains may be categorised as special cases to reflect other 
potential mechanisms such as SN1 or refinements to an existing reaction pathway e.g. MA via its keto-tautomer, N-nitroso derivatives which act as 
hard SN2 or pro-SN2 electrophiles. Assignment to a reaction domain does not automatically signify that a substance is a sensitiser, it may not be 
sufficiently reactive to be sensitising. Substances that exhibit no features indicative of reaction potential are denoted as non-reactive.  
Reaction domain assignments are taken from references a = (20); b = (28); c = (29); d = (25). 
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8 
1-Chloro-2,4-
dinitrobenzene 
(Dinitrochlorobenzene, 
DNCB) 
N(=O)(=O)c(ccc(c1N(=O)(=O))Cl)c1 1 1 1 1 1 SNAra 
9 1-Iodohexane C(CCCCC)I 0 
 
1 1 1 SN2b 
10 1-Naphthol Oc(c(c(ccc1)cc2)c1)c2 1 
 
1 1 1 
Special case pre-
MAb 
11 
1-Phenyl-1,2-
propanedione 
O=C(c(cccc1)c1)C(=O)C 1 
 
1 1 1 SB 
12 2,3-Butanedione O=C(C(=O)C)C 1 
 
1 1 1 SB or MAb 
13 2,4-Dichloronitrobenzene C1=CC(=C(C=C1Cl)Cl)[N+](=O)[O-] 1 
 
0 1 1 SNAr 
14 2,4-Heptadienal CCC=CC=CC=O 1 
 
1 1 1 MAb 
15 
2,5-Diaminotoluene 
sulphate (PTD) 
Nc1ccc(N)c(c1)C 1 1 1 1 1 pre-MAb 
16 2-Acetyl-cyclohexanone O=C(C(C(=O)CCC1)C1)C 0 
 
1 1 1 
SB but not 
reactive enough 
to sensitiseb 
17 2-Aminophenol Oc(c(N)ccc1)c1 1 1 1 1 1 pre-MAb 
18 2-Ethylhexyl acrylate O=C(OCC(CCCC)CC)C=C 1 
 
1 1 1 MA 
19 2-Hydroxyethyl acrylate O=C(OCCO)C=C 1 1 1 1 1 MAb 
20 
2-Hydroxypropyl 
methacrylate 
O=C(OCC(O)C)C(=C)C 0 
 
1 1 0 MAa 
21 2-Mercaptobenzothiazole N(c(c(S1)ccc2)c2)=C1S 1 1 1 1 1 
Weakly reacting 
SN2, Acylb 
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22 
2-Methoxy-4-
methylphenol 
O(c(c(O)ccc1C)c1)C 1 
 
0 0 1 pro/pre-MAb 
23 
2-Methyl-2H-Isothiazol-3-
one 
S1N(C)C(=O)C=C1 1 1 1 1 1 SN2 
24 
2-Nitro-1,4-
phenylendiamine 
O=N(=O)c(c(N)ccc1N)c1 1 1 1 1 1 pro/pre-MAb 
25 2-Phenylpropionaldehyde O=CC(c(cccc1)c1)C 1 
 
1 1 1 SB 
26 3.4-Dihydrocoumarin O=C(Oc(c(ccc1)C2)c1)C2 1  1 0 1 Acyla 
27 3-Aminophenol Oc(cccc1N)c1 1  0 0 1 pro-MAb 
28 
3-Dimethylamino 
propylamine 
N(CCCN)(C)C 1 1 0 1 1 pre-SBb 
29 3-Phenoxypropiononitrile C(Oc1ccccc1)CC(#N) 0  1 0 1 non-reactive 
30 3-Propylidenephthalide O=C(OC(c1cccc2)=CCC)c12 1  1 0 1 Acyla or pre 
31 
4-(4-Hydroxy-4-
methylpentyl)-3-
cyclohexene-1-
carboxaldehyde (Lyral) 
O=CC(CCC(=C1)CCCC(O)(C)C)C1 1 1 1 1 1 SBb 
32 
4-(N-Ethyl-N-2-methan-
sulphonamido-ethyl)-2-
methyl-1,4-
phenylenediamine (CD3) 
Nc1c(C)cc(N(CC)CCNS(=O)(=O)C)cc1 1 
 
1 1 1 pre/pro-MAb 
33 4-Allylanisole O(c(ccc(c1)CC=C)c1)C 1 
 
1 0 1 pro-MAb 
34 4-Aminobenzoic acid C1=CC(=CC=C1C(=O)O)N 0 0 0 0 0 non-reactive 
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35 
4-Ethoxymethylene-2-
phenyl-2-oxazolin-5-one 
(oxazolone) 
N1=C(c2ccccc2)OC(=O)C1=COCC 1 
 
1 1 1 Acylb 
36 4-Hydroxybenzoic acid O=C(O)c(ccc(O)c1)c1 0 
 
0 0 0 non-reactive 
37 4-Methoxyacetophenone COc1ccc(cc1)C(C)=O 0 
 
0 1 0 
SB but not 
reactive enough 
to sensitise 
38 4-Nitrobenzyl bromide O=N(=O)c(ccc(c1)CBr)c1 1 
 
1 1 1 SN2b 
39 5-Methyl-2,3-hexanedione O=C(C(=O)CC(C)C)C 1 1 1 1 1 SBa 
40 6-Methylcoumarin c1c(C)cc2C=CC(=O)Oc2c1 0 
 
0 1 0 
MAa but not 
reactive enough 
to sensitise 
41 α-Amyl cinnamic aldehyde O=CC(=Cc(cccc1)c1)CCCCC 1 1 0 1 1 MAb 
42 
α-methyl-trans-
cinnamaldehyde 
O=CC(=Cc(cccc1)c1)C 1  1 1 1 MAb 
43 Abietic acid 
O=C(O)C(C(C(C(C(=C1)C=C(C2)C(C)C)
C2)(CC3)C)C1)(C3)C 
1 1 1 1 0 
prec due to 
formation of 
hydroperoxides 
44 Aniline Nc(cccc1)c1 1 1 0 0 1 
pre/pro-MA or 
pseudo SB 
45 
Bandrowski’s Base (N,N-
bis(4-aminophenyl)-2,5-
diamino-1,4-quinone-
diimine) 
Nc1ccc(cc1)/N=C3/C=C(/N)C(=Nc2ccc(
N)cc2)C=C3N 
1 
 
1 1 1 pro/pre-MAd 
46 Benzaldehyde O=Cc(cccc1)c1 0 0 0 1 1 
SB but not 
reactive enough 
to sensitiseb 
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47 Benzalkonium chloride CCCCCCCCCCCCCC[N+](C)(C)c1ccccc1 0 0 0 0 0 non-reactive 
48 Benzocaine O=C(OCC)c(ccc(N)c1)c1 0 1 1 1 1 
General aromatic 
amine pre/pro SB 
but free radical 
reactions are also 
possible 
49 Benzoic acid O=C(O)c(cccc1)c1 0 
 
1 0 0 non-reactive 
50 Benzoyl peroxide O=C(OOC(=O)c(cccc1)c1)c(cccc2)c2 1 1 1 0 0 
Special case – 
oxidising agent 
51 Benzyl alcohol C1=CC=C(C=C1)CO 0 
 
0 0 1 
non-reactive, pro-
SN2 (but weak) 
52 Benzyl benzoate O=C(OCc(cccc1)c1)c(cccc2)c2 1 0 0 1 0 Acyl or SN2b 
53 Benzyl bromide BrCc(cccc1)c1 1 
 
1 1 1 SN2b 
54 Benzyl cinnamate 
C1=CC=C(C=C1)COC(=O)/C=C/C2=CC
=CC=C2 
1 
 
0 1 0 MAd 
55 Benzyl salicylate 
C1=CC=C(C=C1)COC(=O)C2=CC=CC=
C2O 
1 0 0 1 0 SN2d 
56 
Benzylidene acetone (4-
phenyl-3-buten-2-one) 
O=C(C=Cc(cccc1)c1)C 1 
 
1 1 1 MAa 
57 
Bisphenol A-diglycidyl 
ether 
O(C1COc(ccc(c2)C(c(ccc(OCC(O3)C3)c4
)c4)(C)C)c2)C1 
1 1 1 1 1 SN2b 
58 Butyl acrylate O=C(OCCCC)C=C 1 
 
1 1 1 MA 
59 Butyl glycidyl ether CCCCOCC1CO1 1 1 1 1 0 SN2b 
60 Chloramine T 
CC1=CC=C(C=C1)S(=O)(=O)[N-
]Cl.[Na+] 
1 
 
1 1 1 Acyl 
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61 Chlorobenzene c(cccc1)(c1)Cl 0 
 
0 0 1 non-reactive 
62 
Chlorpromazine 
hydrochloride 
CN(C)CCCN1c2ccccc2Sc3c1cc(cc3)Cl.Cl 1 1 0 0 1 pro/pre-SB 
63 Cinnamic aldehyde O=CC=Cc(cccc1)c1 1 1 1 1 1 MAa 
64 Cinnamic Alcohol OCC=Cc(cccc1)c1 1 1 1 1 1 
pre/pro-(MA or 
SN2)/pre  
 
65 Citral O=CC=C(CCC=C(C)C)C 1 1 1 1 1 MA, SBb 
66 
Clofibrate (Ethyl (2-(4-
chlorophenoxy)-2-
methylpropanoate) 
CCOC(=O)C(C)(C)Oc1ccc(Cl)cc1 0 
 
0 0 1 non-reactive 
67 Coumarin c1cc2OC(=O)C=Cc2cc1 0 1 0 1 0 
MA but not 
reactive enough 
to sensitiseb 
68 Cyclamen aldehyde O=CC(C)Cc(ccc(c1)C(C)C)c1 1 
 
1 1 0 
Weakly reacting 
SBa 
69 Diethyl acetaldehyde O=CC(CC)CC 1 
 
1 1 1 SBb 
70 Diethyl maleate O=C(OCC)C=CC(=O)OCC 1 1 1 1 1 MAb 
71 Diethyl phthalate CCOC(=O)c1ccccc1C(=O)OCC 0 0 0 0 1 non-reactive 
72 
Dihydroeugenol (2-
methoxy-4-propyl-phenol) 
O(c(c(O)ccc1CCC)c1)C 1 
 
0 1 1 pro-MA 
73 Dimethyl isophthalate COC(=O)C1=CC(=CC=C1)C(=O)OC 0 
 
0 1 0 non-reactive 
74 Diphenylcyclopropenone c(ccc1C(C2=O)=C2c(ccc3)cc3)cc1 1 1 1 1 1 SB 
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75 d-Limonene CC1=CC[C@@H](CC1)C(=C)C 1 0 1 0 1 
pre due to the 
formation of 
hydroperoxides 
76 Ethyl benzoylacetate O=C(OCC)CC(=O)c(cccc1)c1 0 
 
0 1 0 
SB but not 
reactive enough 
to sensitise 
77 Ethyl vanillin O=Cc(ccc(O)c1OCC)c1 0 
 
0 1 0 non-reactive 
78 
Ethylene glycol 
dimethacrylate 
O=C(OCCOC(=O)C(=C)C)C(=C)C 1 1 1 1 1 MA 
79 
Ethylenediamine (free 
base) 
NCCN 1 1 0 1 1 pro-SBb 
80 Eugenol O(c(c(O)ccc1CC=C)c1)C 1 1 1 0 1 pro/pre-MAb,c 
81 Formaldehyde C=O 1 1 1 1 1 
SB or cross 
linkinga 
82 Furil C1=COC(=C1)C(=O)C(=O)C2=CC=CO2 0 
 
1 1 0 SBb 
83 Geraniol OCC=C(CCC=C(C)C)C 1 1 0 1 1 
pre/pro-(MA or 
SN2)/pre also due 
to the formation 
of hydroperoxides 
84 Glutaraldehyde O=CCCCC=O 1 1 1 1 1 
SB or cross 
linkinga 
85 Glycerol OCC(O)CO 0 0 0 0 0 non-reactive 
86 Glyoxal O=CC=O 1 1 1 1 1 SBb 
87 Hexyl cinnamic aldehyde O=CC(=Cc(cccc1)c1)CCCCCC 1 0 0 1 0 MAa 
88 Hydroquinone Oc(ccc(O)c1)c1 1 1 1 1 1 pre-MAa 
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89 Hydroxycitronellal O=CCC(CCCC(O)(C)C)C 1 1 1 1 1 SBa 
90 Imidazolidinyl urea 
O=C(NCNC(=O)NC(NC(=O)N1CO)C1(=
O))NC(NC(=O)N2CO)C2(=O) 
1 1 1 1 1 Acylb 
91 Isoeugenol O(c(c(O)ccc1C=CC)c1)C 1 1 1 1 0 pre-MAa 
92 Isopropanol OC(C)C 0 0 0 0 0 non-reactive 
93 Lactic acid O=C(O)C(O)C 0 0 0 0 0 non-reactive 
94 Lauryl gallate 
O=C(OCCCCCCCCCCCC)c(cc(O)c(O)c1O
)c1 
1 1 1 1 1 pre-MAa,b 
95 Linalool OC(C=C)(CCC=C(C)C)C 1 1 0 0 1 
pre due to 
formation of 
hydroperoxides 
96 Maleic anhydride O=C1OC(=O)C=C1 1 
 
1 0 1 MA or Acyl 
97 Methyl 2-nonynoate O=C(OC)C#CCCCCCC 1 
 
1 1 1 MAb 
98 
Methyl 
methanesulphonate 
O=S(=O)(OC)C 1 
 
1 1 0 SN2b 
99 Methyl salicylate O=C(OC)c(c(O)ccc1)c1 0 0 0 0 0 non-reactive 
100 Methylmethacrylate CC(=C)C(=O)OC 1 1 1 1 0 MA 
101 
N,N-diethyl-3-
methylbenzamide 
CCN(CC)C(=O)C1=CC=CC(=C1)C 0 0 0 0 0 non-reactive 
102 Nonanoic acid O=C(O)CCCCCCCC 1 
 
0 0 1 
non-reactive 
False positive in 
the LLNA 
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103 
Octanoic acid (Caprylic 
acid) 
O=C(O)CCCCCCC 0 0 0 0 1 non-reactive 
104 Oxalic acid anhydrous O=C(O)C(=O)O 1 
 
0 1 1 
Non-reactive 
false positive in 
the LLNA or 
impurity 
105 p-Benzoquinone C1(=O)C=CC(=O)C=C1 1 
 
1 1 1 MAa,b 
106 Penicillin G 
O=C(NC(C(=O)N1C(C(=O)O)C(S2)(C)C
)C12)Cc(cccc3)c3 
1 1 1 0 1 Acylb 
107 Pentachlorophenol Oc(c(c(c(c1Cl)Cl)Cl)Cl)c1Cl 1 0 1 0 1 SNArb 
108 Perillaldehyde C(=C)(C)C1CC=C(C=O)CC1 1 
 
1 1 1 MAb 
109 Phenylacetaldehyde O=CCc(cccc1)c1 1 
 
1 1 1 SBb 
110 Phthalic anhydride O=C(OC(=O)c1cccc2)c12 1 
 
1 0 0 Acyl 
111 Propyl gallate O=C(OCCC)c(cc(O)c(O)c1O)c1 1 1 1 1 1 pre-MAc 
112 Propyl paraben O=C(OCCC)c(ccc(O)c1)c1 0 0 0 1 1 non-reactive 
113 Propylene glycol OCC(O)C 0 0 0 0 0 non-reactive 
114 
p-tert-Butyl-a-ethyl 
hydrocinnamal (Lilial) 
O=CC(C)Cc(ccc(c1)C(C)(C)C)c1 1 1 1 0 1 SBb 
115 Resorcinol Oc(cccc1O)c1 1 1 0 0 1 pro-MAb 
116 Saccharin O=C(NS(=O)(=O)c1cccc2)c12 0 
 
0 0 0 non-reactive 
117 Salicylic acid O=C(O)c(c(O)ccc1)c1 0 0 1 0 1 non-reactive 
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118 Sodium lauryl sulphate CCCCCCCCCCCCOS(=O)(=O)[O-].[Na+] 1 0 0 0 0 
False positive in 
the LLNA 
119 Streptomycin sulfate 
C[C@@H]1[C@]([C@@H]([C@H](O1)O
[C@@H]2[C@H]([C@@H]([C@H]([C@
@H]([C@H]2O)O)NC(=N)N)O)NC(=N)N
)O[C@@H]3[C@@H]([C@H]([C@@H]([
C@H](O3)CO)O)O)NC)(C=O)O.OS(=O)(
=O)O 
0 
 
0 0 0 non-reactive 
120 Sulphanilamide O=S(=O)(N)c(ccc(N)c1)c1 0 
 
0 0 0 non-reactive 
121 Sulphanilic acid O=S(=O)(O)c(ccc(N)c1)c1 0 
 
0 0 0 non-reactive 
122 Tetrachloro-salicylanilide 
O=C(Nc(ccc(c1Cl)Cl)c1)c(c(O)c(cc2Cl)Cl
)c2 
1 1 1 1 1 Special casec 
123 
Tetramethylthiuram 
disulfide 
N(C(=S)SSC(N(C)C)=S)(C)C 1 1 1 1 1 Special case SN2b 
124 Thioglycerol C(C(CS)O)O 1 1 1 0 1 SN2 
125 trans-2-hexenal O=CC=CCCC 1 
 
1 1 1 MAb 
126 Vanillin O=Cc(ccc(O)c1OC)c1 0 0 0 0 0 non-reactive  
127 Xylene CC1=CC=CC=C1C 1 0 0 0 0 
False positive in 
the LLNA 
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2.2 Table 2: List of chemicals briefly presented in Table 1 and assigned by the experts as being pre- 
and/or pro-haptens 
 
# Name LLNA Human DPRA 
Keratino
-Sens™ 
h-CLAT 
Chemical-
based reason 
Additional comments 
1 
1,2-Dibromo-2,4-dicyanobutane 
(MDGN) 
1 1 1 1 1 pre-MA, SN2   
2 1,4-Phenylenediamine 1 1 1 1 1 pre-MA 
Aromatic o- and p-diamine, aminophenol 
or di-phenol alerts13 
3 1-Naphthol 1 
 
1 1 1 pre-MA  Pre-MA via keto tautomer 
4 
2,5-Diaminotoluene sulphate 
(PTD) 
1 1 1 1 1 pre-MA 
Aromatic o- and p-diamine, aminophenol 
or di-phenol alerts 
5 2-Aminophenol 1 1 1 1 1 pre-MA 
Aromatic o- and p-diamine, aminophenol 
or di-phenol alerts 
6 2-Methoxy-4-methylphenol 1 
 
0 0 1 pro/pre-MA 
Quinone methide precursor and/or 
ortho-quinone via OMe alerts 
7 2-Nitro-1,4-phenylendiamine 1 1 1 1 1 pro/pre-MA 
Aromatic o- and p-diamine, aminophenol 
or di-phenol alerts 
8 3-Aminophenol 1 
 
0 0 1 pro-MA 
Aromatic meta: diamines, aminophenols, 
di-phenols, and aromatic monoamines 
9 3-Dimethylamino propylamine 1 1 0 1 1 pre-SB Aliphatic amines alert 
                                           
1 Alert, as referenced in this table, refers to a structural feature that is associated with reaction chemistry that could lead to sensitisation although the 
mechanism is unclear. 
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10 3-Pr4opylidenephthalide 1 
 
1 0 1 Acyl or pre 
Pre - Possible autoxidation to a 
hydroperoxide 
11 
4-(N-Ethyl-N-2-methan-
sulphonamido-ethyl)-2-methyl-
1,4-phenylenediamine (CD3) 
1 
 
1 1 1 pre/pro-MA 
Aromatic o- and p-diamine, aminophenol 
or di-phenol alerts 
12 4-Allylanisole 1 
 
1 0 1 pro-MA 
Quinone methide precursor and/or 
ortho-quinone via OMe alerts 
13 Abietic acid 1 1 1 1 0 pre Autoxidation to hydroperoxides 
14 Aniline 1 1 0 0 1 
pre/pro-MA or 
pseudo SB 
Aromatic meta: diamines, aminophenols, 
di-phenols, and aromatic monoamines. 
Could be pro- or pre- (ring oxidation to 
pre/pro quinone imine, or oxidation of 
NH2 to NO - pseudo SB) or reacting via 
free radical  
15 
Bandrowski’s Base (N,N-bis(4-
aminophenyl)-2,5-diamino-1,4-
quinone-diimine) 
1 
 
1 1 1 pro/pre-MA    
16 Chlorpromazine hydrochloride 1 1 0 0 1 pro/pre-SB 
Aliphatic amines alert. Pro- or pre- SB. -
NCH2CH2CH2N- unit is an alert for 
malondialdehyde, CHOCH2CHO, highly 
reactive 
17 Cinnamyl Alcohol 1 1 1 1 1 
pro/pre-(MA or 
SN2)/pre 
Pro-MA has been assumed to dominate 
but pro-SN2 via sulphate is also a 
possibility 
Pre also due to hydroperoxides 
18 
Dihydroeugenol (2-methoxy-4-
propyl-phenol) 
1 
 
0 1 1 pro-MA 
Quinone methide precursor and/or 
ortho-quinone via OMe alerts 
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19 d-Limonene 1 0 1 0 1 pre Autoxidation to hydroperoxides 
20 Ethylenediamine (free base) 1 1 0 1 1 pro-SB Aliphatic amines alert 
21 Eugenol 1 1 1 0 1 pro/pre-MA 
Quinone methide precursor and/or 
ortho-quinone via OMe alerts  
22 Geraniol 1 1 0 1 1 
pro/pre-(MA or 
SN2)/pre 
Autoxidation to hydroperoxide, 
aldehydesand epoxides. Maybe pro-SN2 
also via sulphation 
23 Hydroquinone 1 1 1 1 1 pre-MA 
Aromatic o- and p-diamine, aminophenol 
or di-phenol alerts 
24 Isoeugenol 1 1 1 1 0 pre-MA 
Quinone methide precursor and/or 
ortho-quinone via OMe alerts 
25 Lauryl gallate 1 1 1 1 1 pre-MA 
Aromatic o- and p-diamine, aminophenol 
or di-phenol alerts 
26 Linalool 1 1 0 0 1 pre Autoxidation to hydroperoxides 
27 Propyl gallate 1 1 1 1 1 pre-MA 
Aromatic o- and p-diamine, aminophenol 
or di-phenol alert 
28 Resorcinol 1 1 0 0 1 pro-MA 
Aromatic meta: diamines, aminophenols, 
di-phenols, and aromatic monoamines 
alerts 
 
Chemicals which autoxidise to hydroperoxides are generally weak sensitisers due to the limited amount of oxidation that can occur during 
exposure/testing. Test results are highly dependent on the sample, therefore these chemicals, as shown in Table 2, are not always 
correctly identified by the in chemico and in vitro assays in the same way as they would not be in the animal models. 
Chemicals containing aromatic ortho (o) and para (p) diamines, aminophenols or di-phenol alerts are correctly predicted by the in 
chemico and in vitro assays as they are with the animal models.  
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Conclusion  
It has long been recognised that in vivo predictive tests for skin sensitisation are not 
perfect, and do not deliver 100% accuracy in terms of the prediction of human hazard 
(30; 31).  Nevertheless, the analysis of the Kern et al. database (25) indicated that the 
LLNA successfully identified all but 2 of the list of pre- and pro-haptens, a success rate of 
approximately 97%.  
The expert group analysis of the EURL ECVAM dataset (n=127) similarly demonstrated 
that a large proportion of the pre- and pro-haptens were correctly identified by the non-
animal methods.  
As a result, it is recommended that negative in vitro data are accepted unless there is a 
compelling scientific argument that a substance is likely to be an exclusively 
metabolically activated pro-hapten.  It is possible that in silico tools such as TIMES-SS 
(8; 9; 10) or the OECD Toolbox (11) would be able to inform such an argument. 
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protein-reactive derivatives 
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to protein-reactive derivatives 
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Sensitization 
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